Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + estradiol + progesterone
- Development stage
- Phase 1
- Lead developer
- Lia Bally
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Transdermal, Oral
01
Overview
This combination therapy consists of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (administered as Wegovy) and menopausal hormone therapy (MHT) comprising estradiol (Estradot) and progesterone (Utrogestan). Developed as part of the DECLARED-CT clinical trial led by Lia Bally at the University of Bern, the regimen targets early postmenopausal women who have or are at risk for type 2 diabetes and obesity. Semaglutide functions by activating GLP-1 receptors to enhance insulin secretion, inhibit glucagon release, and reduce appetite. The addition of MHT is intended to restore estrogen levels, which typically decline during menopause, thereby potentially improving glucose homeostasis and energy metabolism beyond the effects of GLP-1 receptor agonism alone.
- Brand names
- WegovyEstradotUtrogestan
- Other names
- GLP-1RA + MHTsemaglutide + menopausal hormone therapy
02
Targets
ESR1 (ERα)PR-A (Progesterone Receptor A)GLP1R (GLP-1R)ESR2 (ERβ)RB1 (Retinoblastoma-associated Protein)
Beyond the preview
Go deeper on semaglutide + estradiol + progesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + estradiol + progesterone.